
    
      Prolactinoma patients will be assigned to a experimental group that maintains serum prolactin
      levels below 5 ng/mL and a control group that maintains normal serum prolactin levels. After
      that, cabergoline will be maintained at a therapeutic dose for 130 weeks. After cabergoline
      is discontinued, patients will be followed up with serum prolactin measurement for 52 weeks.
    
  